Genmab Announces Initiation Of Share Buy-Back Program Of Up To 370K Shares
https://ml-eu.globenewswire.com/Resource/Download/9c091bde-a4c8-47d7-9e0d-4d25c543eedd
AbbVie – Genmab Present Epcoritamab Data From Lymphoma Trial
AbbVie Inc (NYSE:ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial…
Seagen, Genmab Present Data From Tisotumab Vedotin Clinical Development Program And Additional Cervical Cancer Research At ASCO 2022 Annual Meeting
-- Interim results of tisotumab vedotin plus pembrolizumab from Phase 1b/2 innovaTV 205 trial, showing 41% objective response rate in first-line patients with recurrent or metastatic cervical cancer (r/mCC), to
Morgan Stanley Maintains Underweight on Genmab, Lowers Price Target to $29
Morgan Stanley maintains Genmab (NASDAQ:GMAB) with a Underweight and lowers the price target from $30 to $29.
Analyst Ratings for Genmab
Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings:
SVB Leerink Maintains Market Perform on Genmab, Lowers Price Target to $30
SVB Leerink analyst Jonathan Chang maintains Genmab (NASDAQ:GMAB) with a Market Perform and lowers the price target from $39 to $30.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
Cowen & Co. Initiates Coverage On Genmab with Market Perform Rating, Announces Price Target of $38
Cowen & Co. analyst Yaron Werber initiates coverage on Genmab (NASDAQ:GMAB) with a Market Perform rating and announces Price Target of $38.
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron’s COVID-19 Therapy Decision Pushed, Protagonist’s Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
AbbVie – Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV)